Research ExplorerPublicationsThe MAGIC algorithm probability is a validated response biom...

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

Standard

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. / Srinagesh, Hrishikesh K; Özbek, Umut; Kapoor, Urvi; Ayuk, Francis; Aziz, Mina; Ben-David, Kaitlyn; Choe, Hannah K; DeFilipp, Zachariah; Etra, Aaron; Grupp, Stephan A; Hartwell, Matthew J; Hexner, Elizabeth O; Hogan, William J; Karol, Alexander B; Kasikis, Stelios; Kitko, Carrie L; Kowalyk, Steven; Lin, Jung-Yi; Major-Monfried, Hannah; Mielke, Stephan; Merli, Pietro; Morales, George; Ordemann, Rainer; Pulsipher, Michael A; Qayed, Muna; Reddy, Pavan; Reshef, Ran; Rösler, Wolf; Sandhu, Karamjeet S; Schechter, Tal; Shah, Jay; Sigel, Keith; Weber, Daniela; Wölfl, Matthias; Wudhikarn, Kitsada; Young, Rachel; Levine, John E; Ferrara, James L M.

In: Blood Adv, Vol. 3, No. 23, 10.12.2019, p. 4034-4042.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Srinagesh, HK, Özbek, U, Kapoor, U, Ayuk, F, Aziz, M, Ben-David, K, Choe, HK, DeFilipp, Z, Etra, A, Grupp, SA, Hartwell, MJ, Hexner, EO, Hogan, WJ, Karol, AB, Kasikis, S, Kitko, CL, Kowalyk, S, Lin, J-Y, Major-Monfried, H, Mielke, S, Merli, P, Morales, G, Ordemann, R, Pulsipher, MA, Qayed, M, Reddy, P, Reshef, R, Rösler, W, Sandhu, KS, Schechter, T, Shah, J, Sigel, K, Weber, D, Wölfl, M, Wudhikarn, K, Young, R, Levine, JE & Ferrara, JLM 2019, 'The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease', Blood Adv, vol. 3, no. 23, pp. 4034-4042. https://doi.org/10.1182/bloodadvances.2019000791

APA

Srinagesh, H. K., Özbek, U., Kapoor, U., Ayuk, F., Aziz, M., Ben-David, K., Choe, H. K., DeFilipp, Z., Etra, A., Grupp, S. A., Hartwell, M. J., Hexner, E. O., Hogan, W. J., Karol, A. B., Kasikis, S., Kitko, C. L., Kowalyk, S., Lin, J-Y., Major-Monfried, H., ... Ferrara, J. L. M. (2019). The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv, 3(23), 4034-4042. https://doi.org/10.1182/bloodadvances.2019000791

Vancouver

Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019 Dec 10;3(23):4034-4042. https://doi.org/10.1182/bloodadvances.2019000791

Bibtex

@article{97c414d0c3f34b70be7f58f82aea839c,
title = "The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease",
abstract = "The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP), derived from 2 serum biomarkers, measures damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD). We hypothesized that changes in MAP after treatment could validate it as a response biomarker. We prospectively collected serum samples and clinical stages of acute GVHD from 615 patients receiving hematopoietic cell transplantation in 20 centers at initiation of first-line systemic treatment and 4 weeks later. We computed MAPs and clinical responses and compared their abilities to predict 6-month nonrelapse mortality (NRM) in the validation cohort (n = 367). After 4 weeks of treatment, MAPs predicted NRM better than the change in clinical symptoms in all patients and identified 2 groups with significantly different NRM in both clinical responders (40% vs 12%, P < .0001) and nonresponders (65% vs 25%, P < .0001). MAPs successfully reclassified patients for NRM risk within every clinical grade of acute GVHD after 4 weeks of treatment. At the beginning of treatment, patients with a low MAP that rose above the threshold of 0.290 after 4 weeks of treatment had a significant increase in NRM, whereas patients with a high MAP at onset that fell below that threshold after treatment had a striking decrease in NRM that translated into clear differences in overall survival. We conclude that a MAP measured before and after treatment of acute GVHD is a response biomarker that predicts long-term outcomes more accurately than change in clinical symptoms. MAPs have the potential to guide therapy for acute GVHD and may function as a useful end point in clinical trials.",
author = "Srinagesh, {Hrishikesh K} and Umut {\"O}zbek and Urvi Kapoor and Francis Ayuk and Mina Aziz and Kaitlyn Ben-David and Choe, {Hannah K} and Zachariah DeFilipp and Aaron Etra and Grupp, {Stephan A} and Hartwell, {Matthew J} and Hexner, {Elizabeth O} and Hogan, {William J} and Karol, {Alexander B} and Stelios Kasikis and Kitko, {Carrie L} and Steven Kowalyk and Jung-Yi Lin and Hannah Major-Monfried and Stephan Mielke and Pietro Merli and George Morales and Rainer Ordemann and Pulsipher, {Michael A} and Muna Qayed and Pavan Reddy and Ran Reshef and Wolf R{\"o}sler and Sandhu, {Karamjeet S} and Tal Schechter and Jay Shah and Keith Sigel and Daniela Weber and Matthias W{\"o}lfl and Kitsada Wudhikarn and Rachel Young and Levine, {John E} and Ferrara, {James L M}",
note = "{\textcopyright} 2019 by The American Society of Hematology.",
year = "2019",
month = dec,
day = "10",
doi = "10.1182/bloodadvances.2019000791",
language = "English",
volume = "3",
pages = "4034--4042",
journal = "BLOOD ADV",
issn = "2473-9529",
publisher = "Elsevier BV",
number = "23",

}

RIS

TY - JOUR

T1 - The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

AU - Srinagesh, Hrishikesh K

AU - Özbek, Umut

AU - Kapoor, Urvi

AU - Ayuk, Francis

AU - Aziz, Mina

AU - Ben-David, Kaitlyn

AU - Choe, Hannah K

AU - DeFilipp, Zachariah

AU - Etra, Aaron

AU - Grupp, Stephan A

AU - Hartwell, Matthew J

AU - Hexner, Elizabeth O

AU - Hogan, William J

AU - Karol, Alexander B

AU - Kasikis, Stelios

AU - Kitko, Carrie L

AU - Kowalyk, Steven

AU - Lin, Jung-Yi

AU - Major-Monfried, Hannah

AU - Mielke, Stephan

AU - Merli, Pietro

AU - Morales, George

AU - Ordemann, Rainer

AU - Pulsipher, Michael A

AU - Qayed, Muna

AU - Reddy, Pavan

AU - Reshef, Ran

AU - Rösler, Wolf

AU - Sandhu, Karamjeet S

AU - Schechter, Tal

AU - Shah, Jay

AU - Sigel, Keith

AU - Weber, Daniela

AU - Wölfl, Matthias

AU - Wudhikarn, Kitsada

AU - Young, Rachel

AU - Levine, John E

AU - Ferrara, James L M

N1 - © 2019 by The American Society of Hematology.

PY - 2019/12/10

Y1 - 2019/12/10

N2 - The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP), derived from 2 serum biomarkers, measures damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD). We hypothesized that changes in MAP after treatment could validate it as a response biomarker. We prospectively collected serum samples and clinical stages of acute GVHD from 615 patients receiving hematopoietic cell transplantation in 20 centers at initiation of first-line systemic treatment and 4 weeks later. We computed MAPs and clinical responses and compared their abilities to predict 6-month nonrelapse mortality (NRM) in the validation cohort (n = 367). After 4 weeks of treatment, MAPs predicted NRM better than the change in clinical symptoms in all patients and identified 2 groups with significantly different NRM in both clinical responders (40% vs 12%, P < .0001) and nonresponders (65% vs 25%, P < .0001). MAPs successfully reclassified patients for NRM risk within every clinical grade of acute GVHD after 4 weeks of treatment. At the beginning of treatment, patients with a low MAP that rose above the threshold of 0.290 after 4 weeks of treatment had a significant increase in NRM, whereas patients with a high MAP at onset that fell below that threshold after treatment had a striking decrease in NRM that translated into clear differences in overall survival. We conclude that a MAP measured before and after treatment of acute GVHD is a response biomarker that predicts long-term outcomes more accurately than change in clinical symptoms. MAPs have the potential to guide therapy for acute GVHD and may function as a useful end point in clinical trials.

AB - The Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm probability (MAP), derived from 2 serum biomarkers, measures damage to crypts in the gastrointestinal tract during graft-versus-host disease (GVHD). We hypothesized that changes in MAP after treatment could validate it as a response biomarker. We prospectively collected serum samples and clinical stages of acute GVHD from 615 patients receiving hematopoietic cell transplantation in 20 centers at initiation of first-line systemic treatment and 4 weeks later. We computed MAPs and clinical responses and compared their abilities to predict 6-month nonrelapse mortality (NRM) in the validation cohort (n = 367). After 4 weeks of treatment, MAPs predicted NRM better than the change in clinical symptoms in all patients and identified 2 groups with significantly different NRM in both clinical responders (40% vs 12%, P < .0001) and nonresponders (65% vs 25%, P < .0001). MAPs successfully reclassified patients for NRM risk within every clinical grade of acute GVHD after 4 weeks of treatment. At the beginning of treatment, patients with a low MAP that rose above the threshold of 0.290 after 4 weeks of treatment had a significant increase in NRM, whereas patients with a high MAP at onset that fell below that threshold after treatment had a striking decrease in NRM that translated into clear differences in overall survival. We conclude that a MAP measured before and after treatment of acute GVHD is a response biomarker that predicts long-term outcomes more accurately than change in clinical symptoms. MAPs have the potential to guide therapy for acute GVHD and may function as a useful end point in clinical trials.

U2 - 10.1182/bloodadvances.2019000791

DO - 10.1182/bloodadvances.2019000791

M3 - SCORING: Journal article

C2 - 31816061

VL - 3

SP - 4034

EP - 4042

JO - BLOOD ADV

JF - BLOOD ADV

SN - 2473-9529

IS - 23

ER -